J&J Dreams Of ICONIC Status For Icotrokinra

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

PS1711_Trumpet Player_196485695_1200
J&J and analysts trumpet the efficacy and safety shown by icotrokinra • Source: Shutterstock

More positive data on icotrokinra have lent support to Johnson & Johnson’s claim that its first-in-class oral therapy has to potential to set a new standard of treatment in plaque psoriasis.

More from Strategy

More from Immunological